Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score

Márton Tokodi, Walter Richard Schwertner, Attila Kovács, Zoltán Tősér, Levente Staub, András Sárkány, Bálint Károly Lakatos, Anett Behon, András Mihály Boros, Péter Perge, Valentina Kutyifa, Gábor Széplaki, László Gellér, Béla Merkely, Annamária Kosztin, Márton Tokodi, Walter Richard Schwertner, Attila Kovács, Zoltán Tősér, Levente Staub, András Sárkány, Bálint Károly Lakatos, Anett Behon, András Mihály Boros, Péter Perge, Valentina Kutyifa, Gábor Széplaki, László Gellér, Béla Merkely, Annamária Kosztin

Abstract

Aims: Our aim was to develop a machine learning (ML)-based risk stratification system to predict 1-, 2-, 3-, 4-, and 5-year all-cause mortality from pre-implant parameters of patients undergoing cardiac resynchronization therapy (CRT).

Methods and results: Multiple ML models were trained on a retrospective database of 1510 patients undergoing CRT implantation to predict 1- to 5-year all-cause mortality. Thirty-three pre-implant clinical features were selected to train the models. The best performing model [SEMMELWEIS-CRT score (perSonalizEd assessMent of estiMatEd risk of mortaLity With machinE learnIng in patientS undergoing CRT implantation)], along with pre-existing scores (Seattle Heart Failure Model, VALID-CRT, EAARN, ScREEN, and CRT-score), was tested on an independent cohort of 158 patients. There were 805 (53%) deaths in the training cohort and 80 (51%) deaths in the test cohort during the 5-year follow-up period. Among the trained classifiers, random forest demonstrated the best performance. For the prediction of 1-, 2-, 3-, 4-, and 5-year mortality, the areas under the receiver operating characteristic curves of the SEMMELWEIS-CRT score were 0.768 (95% CI: 0.674-0.861; P < 0.001), 0.793 (95% CI: 0.718-0.867; P < 0.001), 0.785 (95% CI: 0.711-0.859; P < 0.001), 0.776 (95% CI: 0.703-0.849; P < 0.001), and 0.803 (95% CI: 0.733-0.872; P < 0.001), respectively. The discriminative ability of our model was superior to other evaluated scores.

Conclusion: The SEMMELWEIS-CRT score (available at semmelweiscrtscore.com) exhibited good discriminative capabilities for the prediction of all-cause death in CRT patients and outperformed the already existing risk scores. By capturing the non-linear association of predictors, the utilization of ML approaches may facilitate optimal candidate selection and prognostication of patients undergoing CRT implantation.

Keywords: Cardiac resynchronization therapy; Heart failure; Machine learning; Mortality prediction; Precision medicine; Risk stratification.

© The Author(s) 2020. Published by Oxford University Press on behalf of the European Society of Cardiology.

Figures

Figure 1
Figure 1
Computation of survival probabilities: illustrating the methodology through an example case. (A) The outputs of each model were series of class membership probabilities. (B) Cumulative probabilities were calculated by summing these values until the given year of follow-up. (C) To calibrate the cumulative probabilities, Platt’s scaling was performed. Using these calibrated cumulative probabilities, the survival curve could be plotted for each patient. (D) Then, the expected survival time of each patient was estimated from the annual survival probabilities. Pi, the calibrated cumulative probability of all-cause mortality at year i.
Figure 2
Figure 2
Receiver operating characteristic curve analysis of the evaluated risk scores. Calibrated cumulative probabilities were used in the receiver operating characteristic curve analysis.
Figure 3
Figure 3
The 12 most important predictors of all-cause mortality as assessed by the SEMMELWEIS-CRT score. The importance of each feature was quantified by calculating the decrease in the model’s performance (area under the receiver operating characteristic curve) after permuting its values (permutation feature importances method). The higher its value, the more important the feature is. As the values of feature importances were spread over a wide range (more orders of magnitude), base-10 logarithmic transformation was performed to facilitate plotting. CRT, cardiac resynchronization therapy; LVEF, left ventricular ejection fraction; NYHA, New York Heart Failure Association functional class.
Figure 4
Figure 4
Effect of the nine most important continuous features on the calibrated cumulative probability of mortality in the test cohort. Annual probabilities of each patient are marked with different colours (five dots per patient on each plot): 1-year (blue), 2-year (orange), 3-year (green), 4-year (red), and 5-year (purple) calibrated cumulative probabilities. Second order polynomial trendlines are fitted to each year’s probabilities. EF, ejection fraction; GFR, glomerular filtration rate.
Figure 5
Figure 5
Survival analysis of the quartiles. Based on the predicted probability of death, patients were split into four quartiles at each year of follow-up. The survival of the quartiles was visualized on Kaplan–Meier curves and log-rank test was performed for comparison.
Take home figure
Take home figure
Using commonly available pre-implant clinical variables, the machine learning-based SEMMELWEIS-CRT score (available at semmelweiscrtscore.com) can effectively predict all-cause mortality of patients undergoing cardiac resynchronization therapy. AUC, area under the receiver operating characteristic curve; CRT, cardiac resynchronization therapy; ECG, electrocardiogram.
https://www.ncbi.nlm.nih.gov/pmc/articles/instance/7205468/bin/ehz902f6.jpg

References

    1. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V, González-Juanatey JR, Harjola V-P, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GMC, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P; ESC Scientific Document Group. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016;37:2129–2200.
    1. Raatikainen MJP, Arnar DO, Merkely B, Nielsen JC, Hindricks G, Heidbuchel H, Camm J.. A decade of information on the use of cardiac implantable electronic devices and interventional electrophysiological procedures in the European Society of Cardiology Countries: 2017 report from the European Heart Rhythm Association. Europace 2017;19:ii1–ii90.
    1. Goldenberg I, Kutyifa V, Klein HU, Cannom DS, Brown MW, Dan A, Daubert JP, Estes NAM, Foster E, Greenberg H, Kautzner J, Klempfner R, Kuniss M, Merkely B, Pfeffer MA, Quesada A, Viskin S, McNitt S, Polonsky B, Ghanem A, Solomon SD, Wilber D, Zareba W, Moss AJ.. Survival with cardiac-resynchronization therapy in mild heart failure. N Engl J Med 2014;370:1694–1701.
    1. Normand C, Kaye DM, Povsic TJ, Dickstein K.. Beyond pharmacological treatment: an insight into therapies that target specific aspects of heart failure pathophysiology. Lancet 2019;393:1045–1055.
    1. Steffel J, Ruschitzka F.. Superresponse to cardiac resynchronization therapy. Circulation 2014;130:87–90.
    1. Kutyifa V, Geller L, Bogyi P, Zima E, Aktas MK, Ozcan EE, Becker D, Nagy VK, Kosztin A, Szilagyi S, Merkely B.. Effect of cardiac resynchronization therapy with implantable cardioverter defibrillator versus cardiac resynchronization therapy with pacemaker on mortality in heart failure patients: results of a high-volume, single-centre experience. Eur J Heart Fail 2014;16:1323–1330.
    1. Nagy KV, Szeplaki G, Perge P, Boros AM, Kosztin A, Apor A, Molnar L, Szilagyi S, Tahin T, Zima E, Kutyifa V, Geller L, Merkely B.. Quality of life measured with EuroQol-five dimensions questionnaire predicts long-term mortality, response, and reverse remodelling in cardiac resynchronization therapy patients. Europace 2018;20:1506–1512.
    1. Canepa M, Fonseca C, Chioncel O, Laroche C, Crespo-Leiro MG, Coats AJS, Mebazaa A,, Piepoli MF, Tavazzi L, Maggioni AP.. Performance of prognostic risk scores in chronic heart failure patients enrolled in the European Society of Cardiology Heart Failure Long-Term Registry. JACC Heart Fail 2018;6:452–462.
    1. Al’Aref SJ, Anchouche K, Singh G, Slomka PJ,, Kolli KK, Kumar A, Pandey M, Maliakal G, van Rosendael AR, Beecy AN, Berman DS, Leipsic J, Nieman K, Andreini D, Pontone G, Schoepf UJ, Shaw LJ, Chang HJ, Narula J, Bax JJ, Guan Y, Min JK.. Clinical applications of machine learning in cardiovascular disease and its relevance to cardiac imaging. Eur Heart J 2019;40:1975–1986.
    1. Ahmad T, Lund Lars H, Rao P, Ghosh R, Warier P, Vaccaro B, Dahlström U, O’Connor Christopher M, Felker GM, Desai Nihar R.. Machine learning methods improve prognostication, identify clinically distinct phenotypes, and detect heterogeneity in response to therapy in a large cohort of heart failure patients. J Am Heart Assoc 7:e008081..
    1. Motwani M, Dey D, Berman DS, Germano G, Achenbach S, Al-Mallah MH, Andreini D, Budoff MJ, Cademartiri F, Callister TQ, Chang HJ, Chinnaiyan K, Chow BJ, Cury RC, Delago A, Gomez M, Gransar H, Hadamitzky M,, Hausleiter J, Hindoyan N, Feuchtner G, Kaufmann PA, Kim YJ, Leipsic J, Lin FY, Maffei E, Marques H, Pontone G, Raff G, Rubinshtein R, Shaw LJ, Stehli J, Villines TC, Dunning A, Min JK, Slomka PJ.. Machine learning for prediction of all-cause mortality in patients with suspected coronary artery disease: a 5-year multicentre prospective registry analysis. Eur Heart J 2017;38:500–507.
    1. Mortazavi BJ, Downing NS, Bucholz EM, Dharmarajan K, Manhapra A, Li SX, Negahban SN, Krumholz HM.. Analysis of machine learning techniques for heart failure readmissions. Circ Cardiovasc Qual Outcomes 2016;9:629–640.
    1. Kalscheur MM, Kipp RT, Tattersall MC, Mei C, Buhr KA, DeMets DL, Field ME, Eckhardt LL, Page CD.. Machine learning algorithm predicts cardiac resynchronization therapy outcomes: lessons from the COMPANION trial. Circ Arrhythm Electrophysiol 2018;11:e005499.
    1. Feeny AK, Rickard J, Patel D, Toro S, Trulock KM, Park CJ, LaBarbera MA, Varma N, Niebauer MJ, Sinha S, Gorodeski EZ, Grimm RA, Ji X, Barnard J, Madabhushi A, Spragg DD, Chung MK.. Learning prediction of response to cardiac resynchronization therapy. Circ Arrhythm Electrophysiol 2019;12:e007316..
    1. Cikes M, Sanchez-Martinez S, Claggett B, Duchateau N, Piella G, Butakoff C, Pouleur AC, Knappe D, Biering-Sorensen T, Kutyifa V, Moss A, Stein K, Solomon SD, Bijnens B.. Machine learning-based phenogrouping in heart failure to identify responders to cardiac resynchronization therapy. Eur J Heart Fail 2019;21:74–85.
    1. Gasparini M, Klersy C, Leclercq C, Lunati M, Landolina M, Auricchio A, Santini M, Boriani G, Proclemer A, Leyva F.. Validation of a simple risk stratification tool for patients implanted with cardiac resynchronization therapy: the VALID-CRT risk score. Eur J Heart Fail 2015;17:717–724.
    1. Hoke U, Mertens B, Khidir MJH, Schalij MJ, Bax JJ, Delgado V, Ajmone Marsan N.. Usefulness of the CRT-SCORE for shared decision making in cardiac resynchronization therapy in patients with a left ventricular ejection fraction of ≤35. Am J Cardiol 2017;120:2008–2016.
    1. Khatib M, Tolosana JM, Trucco E, Borràs R, Castel A, Berruezo A, Doltra A, Sitges M, Arbelo E, Matas M, Brugada J, Mont L.. EAARN score, a predictive score for mortality in patients receiving cardiac resynchronization therapy based on pre-implantation risk factors. Eur J Heart Fail 2014;16:802–809.
    1. Providencia R, Marijon E, Barra S, Reitan C, Breitenstein A, Defaye P, Papageorgiou N, Duehmke R, Winnik S, Ang R, Klug D, Gras D, Oezkartal T, Segal OR, Deharo JC, Leclercq C, Lambiase PD, Fauchier L, Bordachar P, Steffel J, Sadoul N, Piot O, Borgquist R, Agarwal S, Chow A, Boveda S.. Usefulness of a clinical risk score to predict the response to cardiac resynchronization therapy. Int J Cardiol 2018;260:82–87.
    1. Levy WC, Mozaffarian D, Linker DT, Sutradhar SC, Anker SD, Cropp AB, Anand I, Maggioni A, Burton P, Sullivan MD, Pitt B, Poole-Wilson PA, Mann DL, Packer M.. The Seattle Heart Failure Model: prediction of survival in heart failure. Circulation 2006;113:1424–1433.
    1. Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T, Carson P, DiCarlo L, DeMets D, White BG, DeVries DW, Feldman AM.. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004;350:2140–2150.
    1. Moss AJ, Hall WJ, Cannom DS, Klein H, Brown MW, Daubert JP, Estes NAM, Foster E, Greenberg H, Higgins SL, Pfeffer MA, Solomon SD, Wilber D, Zareba W.. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med 2009;361:1329–1338.
    1. Allen LA, Matlock DD, Shetterly SM, Xu S, Levy WC, Portalupi LB, McIlvennan CK, Gurwitz JH, Johnson ES, Smith DH, Magid DJ.. Use of risk models to predict death in the next year among individual ambulatory patients with heart failure. JAMA Cardiol 2017;2:435–441.
    1. Sengupta PP, Kulkarni H, Narula J.. Prediction of abnormal myocardial relaxation from signal processed surface ECG. J Am Coll Cardiol 2018;71:1650–1660.
    1. Churpek MM, Yuen TC, Winslow C, Meltzer DO, Kattan MW, Edelson DP.. Multicenter comparison of machine learning methods and conventional regression for predicting clinical deterioration on the wards. Crit Care Med 2016;44:368–374.
    1. Weiss JC, Natarajan S, Peissig PL, McCarty CA, Page D.. Machine learning for personalized medicine: predicting primary myocardial infarction from electronic health records. AI Mag. 2012;33:33–45.
    1. Pocock SJ, Ariti CA, McMurray JJV, Maggioni A, Køber L, Squire IB, Swedberg K, Dobson J, Poppe KK, Whalley GA, Doughty RN; on behalf of the Meta-Analysis Global Group in Chronic Heart Failure. Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies. Eur Heart J 2013;34:1404–1413.
    1. Daimee UA, Moss AJ, Biton Y, Solomon SD, Klein HU, McNitt S, Polonsky B, Zareba W, Goldenberg I, Kutyifa V.. Long-term outcomes with cardiac resynchronization therapy in patients with mild heart failure with moderate renal dysfunction. Circ Heart Fail 2015;8:725–732.
    1. Cleland JG, Abraham WT, Linde C, Gold MR, Young JB, Claude Daubert J, Sherfesee L, Wells GA, Tang AS.. An individual patient meta-analysis of five randomized trials assessing the effects of cardiac resynchronization therapy on morbidity and mortality in patients with symptomatic heart failure. Eur Heart J 2013;34:3547–3556.
    1. Zeitler EP, Friedman DJ, Daubert JP, Al-Khatib SM, Solomon SD, Biton Y, McNitt S, Zareba W, Moss AJ, Kutyifa V.. Multiple comorbidities and response to cardiac resynchronization therapy: MADIT-CRT long-term follow-up. J Am Coll Cardiol 2017;69:2369–2379.

Source: PubMed

3
Subscribe